Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Tokai J Exp Clin Med ; 44(3): 40-44, 2019 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-31448394

RESUMO

Bevacizumab is an effective drug for recurrent/advanced cervical cancer. A 59-year-old patient diagnosed with FIGO stage I B2 squamous cell carcinoma of the cervix at our hospital was treated with concurrent chemoradiotherapy as initial treatment. The outcome was judged as close to CR. Local recurrence in the irradiation field and paraaortic lymph node metastasis were noted 2 months after completion of this treatment. Chemotherapy of bevacizumab combined with paclitaxel plus carboplatin (TC) was initiated for recurrent cervical cancer. At 17 days after the 4th cycle, abdominal pain suddenly developed, and a close examination detected free air on abdominal CT, based on which intestinal perforation was diagnosed. Laparoscopic surgery performed to investigate the intraabdominal cavity showed that the small intestine was perforated at 2 sites. These were treated with laparoscopy-assisted partial resection of the small intestine and functional end-to-end anastomosis. Drug therapy for the recurrent cervical cancer was considered, but the primary disease rapidly aggravated and the patient died of the primary disease 11 months after completion of the initial treatment.


Assuntos
Anastomose Cirúrgica/métodos , Anti-Inflamatórios não Esteroides/efeitos adversos , Bevacizumab/efeitos adversos , Carcinoma de Células Escamosas/terapia , Perfuração Intestinal/induzido quimicamente , Perfuração Intestinal/cirurgia , Intestino Delgado/cirurgia , Laparoscopia/métodos , Recidiva Local de Neoplasia/terapia , Neoplasias do Colo do Útero/terapia , Anti-Inflamatórios não Esteroides/administração & dosagem , Bevacizumab/uso terapêutico , Quimiorradioterapia , Evolução Fatal , Feminino , Humanos , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...